CR9266A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Info

Publication number
CR9266A
CR9266A CR9266A CR9266A CR9266A CR 9266 A CR9266 A CR 9266A CR 9266 A CR9266 A CR 9266A CR 9266 A CR9266 A CR 9266A CR 9266 A CR9266 A CR 9266A
Authority
CR
Costa Rica
Prior art keywords
glucagon
compositions
methods
similar
peptide agonists
Prior art date
Application number
CR9266A
Other languages
English (en)
Inventor
T O'neil Karyn
O'neil John
Picha Kristen
Xu Gang
Lark Michael
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CR9266A publication Critical patent/CR9266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
CR9266A 2004-12-22 2007-07-20 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos CR9266A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63831304P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
CR9266A true CR9266A (es) 2008-09-09

Family

ID=37962937

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9266A CR9266A (es) 2004-12-22 2007-07-20 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Country Status (17)

Country Link
US (1) US20070128193A1 (es)
EP (1) EP1843788A4 (es)
JP (1) JP2008525477A (es)
KR (1) KR20070090036A (es)
CN (1) CN101415439A (es)
AU (1) AU2005337493A1 (es)
BR (1) BRPI0519241A2 (es)
CA (1) CA2592065A1 (es)
CR (1) CR9266A (es)
EA (1) EA200701362A1 (es)
IL (1) IL183940A0 (es)
MX (1) MX2007007602A (es)
NI (1) NI200700158A (es)
NO (1) NO20073814L (es)
SG (1) SG158158A1 (es)
WO (1) WO2007046834A2 (es)
ZA (1) ZA200706030B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
DK2314298T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Microparticles comprising diketopiperazinsalte for drug delivery
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Ｇｌｐ−１分子と制吐剤との医薬製剤
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US20070148140A1 (en) * 2005-12-28 2007-06-28 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2300083T3 (da) 2008-06-20 2013-07-22 Mannkind Corp Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US20110020392A1 (en) * 2008-10-14 2011-01-27 Salubrious Pharmaceutical, Llc Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US20140045754A1 (en) * 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US9950038B2 (en) * 2011-08-05 2018-04-24 The Trustees Of The Universiy Of Pennsylvania Methods and compositions for inhibiting delayed graft function
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US20150018271A1 (en) * 2012-03-01 2015-01-15 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105504026B (zh) * 2015-12-24 2018-12-07 广东医科大学 一种pac1-r和glp-1r的双向激动剂ot23及应用
EP3470424A4 (en) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP4161577A1 (en) 2020-06-03 2023-04-12 Københavns Universitet Glp1r agonist nmdar antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
KR20050033563A (ko) * 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
CA2563379A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
CA2592065A1 (en) 2007-04-26
EA200701362A1 (ru) 2008-08-29
NI200700158A (es) 2008-05-13
SG158158A1 (en) 2010-01-29
BRPI0519241A2 (pt) 2009-01-06
US20070128193A1 (en) 2007-06-07
CN101415439A (zh) 2009-04-22
KR20070090036A (ko) 2007-09-04
EP1843788A4 (en) 2009-11-18
ZA200706030B (en) 2009-12-30
EP1843788A2 (en) 2007-10-17
NO20073814L (no) 2007-09-14
WO2007046834A3 (en) 2009-06-18
JP2008525477A (ja) 2008-07-17
IL183940A0 (en) 2007-10-31
WO2007046834A2 (en) 2007-04-26
MX2007007602A (es) 2007-12-07
AU2005337493A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
CR9266A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos
CR8706A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos, usos
CR10619A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
FR2900573B1 (fr) Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
DE602005027899D1 (de) Mundpflegezusammensetzung mit dem extrakt von unoxidierter kamelie
DK1888031T3 (da) GLP-1-analogformuleringer
FR2885904B1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation
NO20050132D0 (no) Vaksinesammensetning
DE602005005587D1 (de) Haarkosmetische Zusammensetzung
DE602005012006D1 (de) Haarkosmetische Zusammensetzung
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
BRPI0719497A2 (pt) "composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
DE602005021571D1 (de) Haarkosmetische Zusammensetzung
ITMI20020189A0 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
DK1812120T3 (da) Hudbeskyttende, alkalinitetskontrollerende præparat og anvendelsen deraf
ITRM20060367A1 (it) Muteine del hngf usi terapeutici e composizioni farmaceutiche
DE602004024220D1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
DK1784174T3 (da) Famaceutisk sammensætning omfattende gabapentin
HK1103279A1 (en) Composition, extract thereof and pharmaceutical use thereof
FR2863874B1 (fr) Composition demaquillante
FR2879924B1 (fr) Composition cosmetique amincissante
FR2901554B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
IL186307A0 (en) Human glp-1 mimetibodies, compositions, methods and uses
ZA200608999B (en) Human GLP-1 mimetibodies, compositions, methods and uses
CL2004000184A1 (es) Forma polimorfa cristalina del monohidrato de 4-ciclopentilresorcinol, composicion farmaceutica y su uso para reducir la pigmentacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)